Know Cancer

or
forgot password

Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host


Phase 2
N/A
N/A
Not Enrolling
Both
Hematological Malignancy, Neoplasm Metastasis

Thank you

Trial Information

Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host


Inclusion Criteria:



- Patients with hematologic malignancy or metastatic solid tumor relapsing following
allogeneic bone marrow or blood stem cell transplantation (alloBMT) or
non-myeloablative stem cell transplantation resistant to DLI with no GVHD when taken
off anti-GVHD prophylaxis.

- Patients with documented chimerism to confirm induction of host-vs-graft
transplantation tolerance.

Exclusion Criteria:

- Patients not consenting to participate in the study, or minors without approved
parental consent.

- Patients with other diseases or complications that may limit their life span other
than their basic disease.

- Pregnant or lactating women.

- Non-compliant patients or patients with poor performance status with life expectancy,
e.g. 6 weeks.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Introducing more effective graft vs leukemia and graft vs tumor effects with immune donor lymphocytes in patients relapsing following allogeneic bone marrow or blood stem cell transplantation

Principal Investigator

Shimon Slavin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hadassah Medical Organization

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

240801-HMO-CTIL

NCT ID:

NCT00149032

Start Date:

August 2001

Completion Date:

Related Keywords:

  • Hematological Malignancy
  • Neoplasm Metastasis
  • Metastatic solid tumor
  • Neoplasms
  • Neoplasm Metastasis
  • Hematologic Neoplasms

Name

Location